Home
Categories
EXPLORE
True Crime
Comedy
Business
Society & Culture
Sports
History
Fiction
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/a0/f3/b7/a0f3b787-bac2-8259-9747-c7e3d53fa9ca/mza_8952235022428513734.jpg/600x600bb.jpg
Few & Far Between: How Biotech Gets Built
Chris O'Brien
35 episodes
1 day ago
Welcome to Few & Far Between! Chris O'Brien, CEO of Biorasi, is your host for fascinating conversations - from clinical research and policymakers to biotech innovators and industry leaders.
Show more...
Life Sciences
Health & Fitness,
Mental Health,
Medicine,
Science
RSS
All content for Few & Far Between: How Biotech Gets Built is the property of Chris O'Brien and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Welcome to Few & Far Between! Chris O'Brien, CEO of Biorasi, is your host for fascinating conversations - from clinical research and policymakers to biotech innovators and industry leaders.
Show more...
Life Sciences
Health & Fitness,
Mental Health,
Medicine,
Science
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/a0/f3/b7/a0f3b787-bac2-8259-9747-c7e3d53fa9ca/mza_8952235022428513734.jpg/600x600bb.jpg
Episode 53: Frank David, Founder and Managing Director, Pharmagellan
Few & Far Between: How Biotech Gets Built
50 minutes 46 seconds
8 months ago
Episode 53: Frank David, Founder and Managing Director, Pharmagellan
How do mission, vision, and data analysis fit into today's biotech goals? Host Chris O'Brien welcomes Frank David, Founder and Managing Director of Pharmagellan to the podcast. Tune in as we explore R&D strategy, de-risking tactics, and how to think about valuation. Listen in to the latest episode of the Biorasi Few & Far Between podcast today!    
Few & Far Between: How Biotech Gets Built
Welcome to Few & Far Between! Chris O'Brien, CEO of Biorasi, is your host for fascinating conversations - from clinical research and policymakers to biotech innovators and industry leaders.